Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03699462
Other study ID # 4-2018-0670
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 13, 2018
Est. completion date October 17, 2020

Study information

Verified date October 2020
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is being revealed that the more severe the damage of the endothelial glycocalyx (EG) layer, the more likely it is that the prognosis of the patients is poor. For that reason, research is being actively conducted on methods for reducing damage and promoting recovery of the EG layer.The natural regeneration process of the EG layer is up to 7 days. Considering the fact that it is quiet slow, reducing the damage of EG layer is considered to be very important for improving the prognosis of patients undergoing surgery, but there is no clinically proven method. One of the ways receiving attention to reduce damage of EG layer is to stabilize the layer through fluid therapy with albumin. The purpose of this study is to compare the protective effect of the EG layer according to the type of fluid (balanced crystalloid solution vs. 5% albumin) during surgery in patients undergoing off-pump coronary artery bypass surgery.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date October 17, 2020
Est. primary completion date October 17, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Patients over 20 years of age undergoing off-pump coronary artery bypass surgery Exclusion Criteria: - Emergency operation - Minimally-invasive surgery (under one-lung ventilation) - Chronic kidney disease (eGFR<30 ml/min/1.73m2) or Dialysis - Acute kidney injury - Infectious disease - Preoperative steroid use - Malignancy - Reported allergic reaction to albumin preparations - Patients who participated in other clinical studies that could affect prognosis - Patients who have difficulty in reading the informed consent and voluntarily agreeing to participate in the study

Study Design


Related Conditions & MeSH terms

  • Coronary Artery Occlusive Disease(CAOD)

Intervention

Drug:
Plasma solution-A injection
The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
5% Albumin
The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery

Locations

Country Name City State
Korea, Republic of Division of Cardiac Anesthesiology, Department of Anesthesiology and Pain Medicine, Cardiovascular Hospital, Severance Hospital, Yonsei University College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma concentration of Syndecan-1 The investigators compare the protective effect of EG layer according to the type of fluid used during surgery in patients undergoing off-pump coronary artery bypass surgery. (Comparison of the plasma concentration of Syndecan-1 between the two groups.) Before induction of anesthesia (1-hour before the start of surgery)
Primary Plasma concentration of Syndecan-1 The investigators compare the protective effect of EG layer according to the type of fluid used during surgery in patients undergoing off-pump coronary artery bypass surgery. (Comparison of the plasma concentration of Syndecan-1 between the two groups.) At the time of returning the heart in place after coronary artery anastomoses (1~2 hour before the end of surgery)
Primary Plasma concentration of Syndecan-1 The investigators compare the protective effect of EG layer according to the type of fluid used during surgery in patients undergoing off-pump coronary artery bypass surgery. (Comparison of the plasma concentration of Syndecan-1 between the two groups.) At the time of sternum being closed (30min~1hr before the end of surgery)
Secondary Plasma concentration of Haparan sulfate Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. Before induction of anesthesia (1hr before the start of surgery)
Secondary Plasma concentration of Haparan sulfate Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. At the time of returning the heart in place after coronary artery anastomoses (1~2hr before the end of surgery)
Secondary Plasma concentration of Haparan sulfate Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. At the time of sternum being closed (30min~1hr before the end of surgery)
Secondary Plasma concentration of ANP Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. Before induction of anesthesia (1hr before the start of surgery)
Secondary Plasma concentration of ANP Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. At the time of returning the heart in place after coronary artery anastomoses (1~2hr before the end of surgery)
Secondary Plasma concentration of TNF-a/IL-6 Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. Before induction of anesthesia (1hr before the start of surgery)
Secondary Plasma concentration of TNF-a/IL-6 Heparan sulfate is one of the indicators of EG damage, and ANP & TNF-a, IL-6 are known to correlate with EG damage. So in this study, the investigators measure the plasma concentrations of Haparan sulfate, ANP & TNF-a, IL-6 as well as Syndecan-1, and also identify the overall short-term prognosis of the patients. At the time of sternum being closed (30min~1hr before the end of surgery)
Secondary Composite rate of morbidity and mortality Composite morbidity and mortality (Mortality, Stroke, Re-operation, Sternal infection, Prolonged ventilation, Renal dysfunction) If the hospitalization period is within 30 days, follow-up is done up to 30 days.
Secondary Composite rate of morbidity and mortality Composite morbidity and mortality (Mortality, Stroke, Re-operation, Sternal infection, Prolonged ventilation, Renal dysfunction) If the hospitalization period exceeds 30 days, follow-up is done throughout the hospitalization period.